TKT Hemophilia Gene Therapy Trial Halted Despite No Evidence Of Problems
Executive Summary
The suspension of Transkaryotic Therapies' gene therapy trial at Beth Israel Deaconess Medical Center could signal the beginning of a trend of gene therapy trial suspensions as a cautionary measure even if the study shows no sign of problems.
You may also be interested in...
TKT European Company To Be Led By Ex-P&U Genotropin Team
Transkarayotic Therapies' newly established European company will be headed by executives who led the EU and Japan launch of Pharmacia & Upjohn's Genotropin.
TKT European Company To Be Led By Ex-P&U Genotropin Team
Transkarayotic Therapies' newly established European company will be headed by executives who led the EU and Japan launch of Pharmacia & Upjohn's Genotropin.
UPenn Engages CRO To Monitor AE Reporting For Gene Therapy Trials
The University of Pennsylvania's gene therapy institute has engaged a contract research organization to monitor adverse event reporting and other administrative and regulatory requirements for its gene therapy trials.